Advertisement Pharmaceutical Business review - Page 4709 of 5290 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 17, 2026

Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy

Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive sleep apnoea syndrome (OSAS) and for narcolepsy types 1 and 2.

Wakix is an orally administered therapy that modulates sleep–wake pathways. Credit: eldar nurkovic / Shutterstock.com.